Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T07958
|
||||
Former ID |
TTDI01917
|
||||
Target Name |
Erythropoietin ligand
|
||||
Gene Name |
EPO
|
||||
Synonyms |
Epoetin; Erythropoietin; EPO
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Anemia [ICD9: 280-285; ICD10: D50-D64] | ||||
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63] | |||||
Depression; Diabetic neuropathy; Mood disorder [ICD9:311, 250, 250.6, 356.0, 356.8; ICD10: F30-F39, E11.40] | |||||
Unspecified [ICD code not available] | |||||
Function |
Erythropoietin is the principal hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.
|
||||
UniProt ID | |||||
Sequence |
MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHC
SLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQL HVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKL KLYTGEACRTGDR |
||||
Drugs and Mode of Action | |||||
Drug(s) | ARA 290 | Drug Info | Phase 2 | Depression; Diabetic neuropathy; Mood disorder | [549308] |
MK-2578 | Drug Info | Phase 2 | Anemia | [522772] | |
Erythropoietin-transfected autologous cell therapy | Drug Info | Phase 1/2 | Anemia | [522139] | |
GC-1113 | Drug Info | Phase 1 | Anemia | [523499] | |
Long-acting erythropoietin conjugate | Drug Info | Phase 1 | Anemia | [522889] | |
FC EPO | Drug Info | Discontinued in Phase 1 | Anemia | [548647] | |
GLY-515n | Drug Info | Terminated | Cerebrovascular ischaemia | [548665] | |
Modulator | ARA 290 | Drug Info | |||
Erythropoietin-transfected autologous cell therapy | Drug Info | [525362] | |||
GC-1113 | Drug Info | [531927] | |||
GLY-515n | Drug Info | [548666] | |||
Long-acting erythropoietin conjugate | Drug Info | ||||
Research programme: erythropoietin oral - HanAll Biopharma | Drug Info | ||||
Agonist | FC EPO | Drug Info | [531957] | ||
MK-2578 | Drug Info | [525376] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
HIF-1 signaling pathway | |||||
PI3K-Akt signaling pathway | |||||
Jak-STAT signaling pathway | |||||
Hematopoietic cell lineage | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Signaling events mediated by Stem cell factor receptor (c-Kit) | |||||
EPO signaling pathway | |||||
HIF-1-alpha transcription factor network | |||||
Reactome | Regulation of gene expression by Hypoxia-inducible Factor | ||||
WikiPathways | EPO Receptor Signaling | ||||
Hematopoietic Stem Cell Differentiation | |||||
Differentiation Pathway | |||||
Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | |||||
References | |||||
Ref 522139 | ClinicalTrials.gov (NCT00542568) Safety and Efficacy of Sustained Erythropoietin Therapy. U.S. National Institutes of Health. | ||||
Ref 522772 | ClinicalTrials.gov (NCT00968617) A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002). U.S. National Institutes of Health. | ||||
Ref 522889 | ClinicalTrials.gov (NCT01030315) A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects. U.S. National Institutes of Health. | ||||
Ref 523499 | ClinicalTrials.gov (NCT01363934) To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin. U.S. National Institutes of Health. | ||||
Ref 548647 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027346) | ||||
Ref 525362 | Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther. 2009 Feb;17(2):369-72. doi: 10.1038/mt.2008.270. Epub 2008 Dec 16. | ||||
Ref 531927 | A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia. Arch Pharm Res. 2012 May;35(5):757-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.